Roy Buchanan
Stock Analyst at JMP Securities
(4.49)
# 309
Out of 5,113 analysts
54
Total ratings
51.92%
Success rate
34.17%
Average return
Main Sectors:
Stocks Rated by Roy Buchanan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ASMB Assembly Biosciences | Initiates: Market Outperform | $38 | $26.47 | +43.56% | 1 | Sep 24, 2025 | |
| DVAX Dynavax Technologies | Reiterates: Market Outperform | $32 | $15.50 | +106.52% | 8 | Aug 22, 2025 | |
| ENTA Enanta Pharmaceuticals | Maintains: Market Outperform | $24 → $25 | $12.84 | +94.70% | 15 | Aug 12, 2025 | |
| PYPD PolyPid | Maintains: Market Outperform | $16 → $14 | $4.67 | +199.79% | 2 | Jun 17, 2025 | |
| ANTX AN2 Therapeutics | Maintains: Market Outperform | $5 → $2 | $1.20 | +66.67% | 9 | May 5, 2025 | |
| INO Inovio Pharmaceuticals | Reiterates: Market Outperform | $18 | $1.51 | +1,096.01% | 3 | Mar 14, 2025 | |
| TPG TPG Inc. | Reiterates: Market Perform | n/a | $60.37 | - | 1 | Feb 13, 2025 | |
| ESPR Esperion Therapeutics | Reiterates: Market Outperform | $7 → $4 | $3.47 | +15.44% | 3 | Feb 11, 2025 | |
| IRWD Ironwood Pharmaceuticals | Maintains: Market Outperform | $23 → $14 | $4.90 | +185.71% | 1 | Jan 30, 2025 | |
| ABVX ABIVAX Société Anonyme | Reiterates: Market Outperform | $33 | $116.07 | -71.57% | 1 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $4 → $5 | $4.23 | +18.20% | 5 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $443 → $448 | $845.69 | -47.03% | 2 | Mar 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $14 → $16 | $7.83 | +104.34% | 1 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $2.24 | - | 2 | Feb 16, 2023 |
Assembly Biosciences
Sep 24, 2025
Initiates: Market Outperform
Price Target: $38
Current: $26.47
Upside: +43.56%
Dynavax Technologies
Aug 22, 2025
Reiterates: Market Outperform
Price Target: $32
Current: $15.50
Upside: +106.52%
Enanta Pharmaceuticals
Aug 12, 2025
Maintains: Market Outperform
Price Target: $24 → $25
Current: $12.84
Upside: +94.70%
PolyPid
Jun 17, 2025
Maintains: Market Outperform
Price Target: $16 → $14
Current: $4.67
Upside: +199.79%
AN2 Therapeutics
May 5, 2025
Maintains: Market Outperform
Price Target: $5 → $2
Current: $1.20
Upside: +66.67%
Inovio Pharmaceuticals
Mar 14, 2025
Reiterates: Market Outperform
Price Target: $18
Current: $1.51
Upside: +1,096.01%
TPG Inc.
Feb 13, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $60.37
Upside: -
Esperion Therapeutics
Feb 11, 2025
Reiterates: Market Outperform
Price Target: $7 → $4
Current: $3.47
Upside: +15.44%
Ironwood Pharmaceuticals
Jan 30, 2025
Maintains: Market Outperform
Price Target: $23 → $14
Current: $4.90
Upside: +185.71%
ABIVAX Société Anonyme
Jan 10, 2025
Reiterates: Market Outperform
Price Target: $33
Current: $116.07
Upside: -71.57%
Aug 2, 2024
Maintains: Market Outperform
Price Target: $4 → $5
Current: $4.23
Upside: +18.20%
Mar 3, 2023
Maintains: Market Outperform
Price Target: $443 → $448
Current: $845.69
Upside: -47.03%
Mar 1, 2023
Maintains: Market Perform
Price Target: $14 → $16
Current: $7.83
Upside: +104.34%
Feb 16, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $2.24
Upside: -